{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-267934","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.046317+00:00","generated_at":"2026-05-16T23:44:38.490915+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"4D Molecular announces positive interim 1.5-3.5 year data for 4D-150 in wet AMD; 79-92% injection reduction","bullets":["Preliminary cash, equivalents and marketable securities $372.2M as of Sept 30, 2025.","Phase 2b recently diagnosed subgroup (Phase 3 comparable): 92% reduction in mean supplemental injections vs aflibercept at 1.5 years.","Phase 2b broad cohort: 82% reduction; Phase 1/2a severe recalcitrant: 79% reduction at 2 years.","Safety: 2.8% (2/71) mild transient IOI within 28 weeks; no new IOI after 28 weeks; no hypotony, endophthalmitis, vasculitis.","Consistent dose response favoring Phase 3 dose (3E10 vg/eye) over lower dose across all cohorts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-267934","json":"https://secwatch.observer/filing/0001193125-25-267934.json","markdown":"https://secwatch.observer/filing/0001193125-25-267934.md","text":"https://secwatch.observer/filing/0001193125-25-267934.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525267934/0001193125-25-267934-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525267934/d280681d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:44:38.490915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}